AtonRa Partners Decreases Stock Position in UiPath Inc. (NYSE:PATH)

AtonRa Partners trimmed its position in shares of UiPath Inc. (NYSE:PATH) by 12.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,696 shares of the healthcare company’s stock after selling 3,068 shares during the quarter. AtonRa Partners’ holdings in UiPath were worth $514,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of UiPath by 7.6% during the third quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock worth $645,916,000 after buying an additional 2,673,718 shares in the last quarter. Glenmede Trust Co. NA grew its stake in UiPath by 3,273.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,564,985 shares of the healthcare company’s stock valued at $26,777,000 after acquiring an additional 1,518,592 shares in the last quarter. FMR LLC raised its holdings in UiPath by 2.9% in the 3rd quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock valued at $277,835,000 after acquiring an additional 463,032 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in UiPath by 179.9% in the 3rd quarter. Los Angeles Capital Management LLC now owns 715,688 shares of the healthcare company’s stock worth $12,245,000 after purchasing an additional 459,965 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in UiPath by 857.7% in the 4th quarter. Federated Hermes Inc. now owns 458,126 shares of the healthcare company’s stock worth $11,380,000 after purchasing an additional 410,288 shares in the last quarter. 62.50% of the stock is owned by institutional investors and hedge funds.

UiPath Price Performance

Shares of PATH stock traded up $0.31 during trading hours on Monday, reaching $19.77. 4,752,185 shares of the stock were exchanged, compared to its average volume of 8,654,434. UiPath Inc. has a 12-month low of $12.38 and a 12-month high of $27.87. The business’s fifty day moving average is $22.08 and its two-hundred day moving average is $21.64. The firm has a market capitalization of $11.25 billion, a P/E ratio of -116.29 and a beta of 0.96.

UiPath (NYSE:PATH) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The firm had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. As a group, equities research analysts predict that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PATH has been the topic of a number of analyst reports. BMO Capital Markets lifted their price objective on UiPath from $24.00 to $28.00 and gave the stock a “market perform” rating in a research report on Thursday, March 14th. Mizuho boosted their price target on shares of UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. KeyCorp began coverage on shares of UiPath in a research report on Monday, April 8th. They set an “overweight” rating and a $27.00 price objective for the company. William Blair began coverage on shares of UiPath in a report on Tuesday, January 2nd. They issued an “outperform” rating on the stock. Finally, Morgan Stanley increased their price target on shares of UiPath from $17.00 to $25.00 and gave the company an “equal weight” rating in a research note on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $27.41.

Insider Activity at UiPath

In related news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $22.47, for a total transaction of $359,520.00. Following the completion of the sale, the chief financial officer now directly owns 103,505 shares of the company’s stock, valued at $2,325,757.35. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 72,000 shares of company stock worth $1,591,360 in the last quarter. Company insiders own 31.03% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.